ES2174097T3 - Secuencias novedosas del termino 3' del genoma del virus de la hepatitis c y usos terapeuticos y diagnosticos de la misma. - Google Patents

Secuencias novedosas del termino 3' del genoma del virus de la hepatitis c y usos terapeuticos y diagnosticos de la misma.

Info

Publication number
ES2174097T3
ES2174097T3 ES96929843T ES96929843T ES2174097T3 ES 2174097 T3 ES2174097 T3 ES 2174097T3 ES 96929843 T ES96929843 T ES 96929843T ES 96929843 T ES96929843 T ES 96929843T ES 2174097 T3 ES2174097 T3 ES 2174097T3
Authority
ES
Spain
Prior art keywords
hcv
sequence
hepatitis
therapeutic
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96929843T
Other languages
English (en)
Inventor
Charles M Rice
Alexander A Kolykhalov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Washington University in St Louis WUSTL
Original Assignee
University of Washington
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Washington University in St Louis WUSTL filed Critical University of Washington
Application granted granted Critical
Publication of ES2174097T3 publication Critical patent/ES2174097T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA INVENCION SE REFIERE AL DESCUBRIMIENTO DE UNA NOVEDOSA SECUENCIA DE ARN EN LA SECUENCIA 3'' TERMINAL DEL GENOMA ARN DEL VIRUS DE LA HEPATITIS C (HCV). SE INCLUYE EN LA INVENCION LA SECUENCIA 3'', SU COMPLEMENTARIA, Y SU USO EN METODOS DIAGNOSTICOS BASADOS EN ACIDOS NUCLEICOS Y PARA EL DESARROLLO Y EVALUACION DE NUEVAS TERAPIAS ANTI-HCV. ESTE ELEMENTO DE LA SECUENCIA, QUE SE CONSERVA ENTRE LOS GENOTIPOS DEL HCV, ES PROBABLE QUE SEA ESENCIAL PARA LA REPLICACION VIRICA, Y QUE SEA NECESARIO PARA LA CONSTRUCCION DE LA LONGITUD COMPLETA DE CLONES DE ADNC DEL HCV CAPACES DE PROPORCIONAR UN ARN INFECCIOSO, PROGENIE VIRICA O REPLICONES HCV COMPETENTES PARA EFECTUAR LA REPLICACION. TALES CLONES FUNCIONALES SON INSTRUMENTOS UTILES PARA LA EVALUACION DE METODOS TERAPEUTICOS Y COMO SUSTRATOS PARA DESARROLLAR DERIVADOS ATENUADOS O INACTIVADOS DEL HCV CANDIDATOS PARA LA VACUNACION CONTRA EL HCV.
ES96929843T 1995-08-29 1996-08-28 Secuencias novedosas del termino 3' del genoma del virus de la hepatitis c y usos terapeuticos y diagnosticos de la misma. Expired - Lifetime ES2174097T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/520,678 US5874565A (en) 1995-08-29 1995-08-29 Nucleic acids comprising a highly conserved novel 3 terminal sequence element of the hepatitis C virus

Publications (1)

Publication Number Publication Date
ES2174097T3 true ES2174097T3 (es) 2002-11-01

Family

ID=24073628

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96929843T Expired - Lifetime ES2174097T3 (es) 1995-08-29 1996-08-28 Secuencias novedosas del termino 3' del genoma del virus de la hepatitis c y usos terapeuticos y diagnosticos de la misma.

Country Status (12)

Country Link
US (5) US5874565A (es)
EP (1) EP0856051B1 (es)
JP (3) JP3911022B2 (es)
AU (1) AU713112B2 (es)
BR (1) BR9610307A (es)
CA (1) CA2230452C (es)
DE (1) DE69620432T2 (es)
ES (1) ES2174097T3 (es)
IL (1) IL123465A (es)
MX (1) MX9801715A (es)
PT (1) PT856051E (es)
WO (1) WO1997008310A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09107970A (ja) * 1995-10-17 1997-04-28 Soyaku Gijutsu Kenkyusho:Kk Ｃ型肝炎ウイルス由来核酸、該核酸を用いたウイルスの検出方法
US5698390A (en) 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US6861212B1 (en) 1987-11-18 2005-03-01 Chiron Corporation NANBV diagnostics and vaccines
US6127116A (en) 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US7235394B1 (en) 1995-08-29 2007-06-26 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US6242187B1 (en) * 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
US7049428B1 (en) 1998-03-04 2006-05-23 Washington University HCV variants
US6649350B2 (en) * 1997-04-09 2003-11-18 California Institute Of Technology Electrochemical sensor using intercalative, redox-active moieties
US6221586B1 (en) 1997-04-09 2001-04-24 California Institute Of Technology Electrochemical sensor using intercalative, redox-active moieties
US6153421A (en) 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof
US20030028011A1 (en) * 1997-07-30 2003-02-06 Parkin Neil T. Compositions and methods for determining susceptibility of hepatitis C virus to anti-viral drugs
US20020034732A1 (en) * 1997-07-30 2002-03-21 Daniel J. Capon Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
EP1036847B1 (en) * 1999-02-03 2004-10-27 Ortho-Clinical Diagnostics, Inc. Oligonucleotide primers for efficient reverse transcription of Hepatitis C Virus (HCV) RNA and methods of use thereof
DE19915178A1 (de) * 1999-04-03 2000-10-05 Univ Mainz Johannes Gutenberg Hepatitis C Virus Zellkultursystem
US7084266B1 (en) * 1999-06-04 2006-08-01 The United States Of America As Represented By The Department Of Health And Human Services Cloned genome of infectious hepatitus C virus of genotype 2A and uses thereof
US6921634B2 (en) * 1999-12-23 2005-07-26 Board Of Regents, The University Of Texas System Replication competent hepatitus C virus and methods of use
US20040005549A1 (en) * 2000-11-07 2004-01-08 Anadys Pharmaceuticals, Inc. Hepatitis C virus constructs characterized by high efficiency replication
WO2002038793A2 (en) 2000-11-07 2002-05-16 Anadys Pharmaceuticals, Inc. Hepatitis c virus constructs characterized by high efficiency replication
US6699657B2 (en) * 2001-01-31 2004-03-02 Bristol-Myers Squibb Company In vitro system for replication of RNA-dependent RNA polymerase (RDRP) viruses
AU2002311897A1 (en) * 2001-05-09 2002-11-18 Third Wave Technologies, Inc. Nucleic acid detection in pooled samples
US20040209831A1 (en) * 2002-02-20 2004-10-21 Mcswiggen James RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
US20060211642A1 (en) * 2001-05-18 2006-09-21 Sirna Therapeutics, Inc. RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
US20050209180A1 (en) * 2001-05-18 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
US20050239205A1 (en) * 2002-01-15 2005-10-27 Amedeo De Tomassi Gb virus b based replicons and replicon enhanced cells
ATE426682T1 (de) * 2002-04-16 2009-04-15 Merck & Co Inc Hepatitis-c-virus-testsysteme
CA2884658A1 (en) 2002-07-26 2004-02-05 Novartis Vaccines And Diagnostics, Inc. Modified small interfering rna molecules and methods of use
US7825488B2 (en) * 2006-05-31 2010-11-02 Advanced Analogic Technologies, Inc. Isolation structures for integrated circuits and modular methods of forming the same
AU2004258750A1 (en) * 2003-07-25 2005-02-03 Centre National De La Recherche Scientifique -Cnrs Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis C
EP1694694B1 (en) * 2003-12-01 2013-01-23 Board Of Regents, The University Of Texas System Replication competent hepatitis c virus and methods of use
WO2005071117A2 (en) * 2004-01-23 2005-08-04 Biomerieux, Inc. Primer and probe design for efficient amplification and detection of hcv 3′ non-translating region
EP1728186A2 (en) 2004-03-02 2006-12-06 Virco Bvba Estimation of clinical cut-offs
KR100894150B1 (ko) * 2004-06-25 2009-04-22 가부시끼가이샤 센단세메이가가꾸겐큐죠 신규한 배열을 가진 ｈｃｖ ｒｎａ
ES2362670T3 (es) 2004-09-24 2011-07-11 Alnylam Pharmaceuticals, Inc Orientación a intermedios de replicación de hebra no codificante de virus monocatenarios por arni.
CA2592099A1 (en) 2004-12-22 2006-06-29 Nucleonics, Inc. Conserved hbv and hcv sequences useful for gene silencing
US7504255B2 (en) * 2006-08-17 2009-03-17 Saint Louis University Compositions and methods for generation of infectious hepatitis C virus in immortalized human hepatocytes
EP2094300B1 (en) * 2006-12-22 2012-12-26 Rajesh Shah Medicinal formulation for the treatment for hepatitis c
US20080299568A1 (en) * 2007-04-27 2008-12-04 Scott Johnson Materials and methods for detection of hepatitis c virus
AU2008320529B2 (en) * 2007-10-31 2013-10-24 Debiopharm International Sa Near full-genome assay of HCV drug resistance
US20100323344A1 (en) * 2009-06-18 2010-12-23 Ferguson Monique R Detection of hepatitis C virus RNA
US20110070199A1 (en) * 2009-09-21 2011-03-24 Scheiber Ii Lane Bernard Adaptable modified virus vector to deliver ribosomal ribonucleic acid combined with messenger ribonucleic acid as a medical treatment device to manage diabetes mellitus and other protein deficient dieases
US9070258B1 (en) * 2013-05-29 2015-06-30 Melissa P. Ilieva Automated bingo caller assembly

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714596A (en) 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US5698390A (en) 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
EP0510952A1 (en) * 1991-04-26 1992-10-28 Immuno Japan Inc. Oligonucleotide primers and their application for high-fidelity detection of non-a, non-b hepatitis virus
AU659649B2 (en) * 1991-06-10 1995-05-25 Lucky Limited Hepatitis C diagnostics and vaccines
ATE172500T1 (de) * 1991-07-31 1998-11-15 Hoffmann La Roche Verfahren und reagenzien zur bestimmung von bakterien in der zerebrospinalen flüssigkeit
TW275068B (es) * 1993-09-24 1996-05-01 American Cyanamid Co

Also Published As

Publication number Publication date
US6297003B1 (en) 2001-10-02
DE69620432D1 (de) 2002-05-08
US20030027130A1 (en) 2003-02-06
DE69620432T2 (de) 2002-11-21
US20030054341A1 (en) 2003-03-20
AU713112B2 (en) 1999-11-25
IL123465A (en) 2004-09-27
JP4031511B2 (ja) 2008-01-09
US6943246B2 (en) 2005-09-13
JP3911022B2 (ja) 2007-05-09
CA2230452A1 (en) 1997-03-06
PT856051E (pt) 2002-09-30
EP0856051B1 (en) 2002-04-03
JP4077016B2 (ja) 2008-04-16
EP0856051A1 (en) 1998-08-05
WO1997008310A1 (en) 1997-03-06
JP2007125028A (ja) 2007-05-24
IL123465A0 (en) 1998-09-24
AU6909796A (en) 1997-03-19
BR9610307A (pt) 1999-07-06
MX9801715A (es) 1998-05-31
US20030017586A1 (en) 2003-01-23
JPH11514214A (ja) 1999-12-07
US5874565A (en) 1999-02-23
CA2230452C (en) 2008-10-21
JP2007125027A (ja) 2007-05-24

Similar Documents

Publication Publication Date Title
ES2174097T3 (es) Secuencias novedosas del termino 3' del genoma del virus de la hepatitis c y usos terapeuticos y diagnosticos de la misma.
Krieger et al. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations
Ito et al. The 3′-untranslated region of hepatitis C virus RNA enhances translation from an internal ribosomal entry site
Friebe et al. Sequences in the 5′ nontranslated region of hepatitis C virus required for RNA replication
CO5590973A2 (es) Acido nucleico de adenovirus de simio y secuiencias de aminoacidos, vectores que contienen los mismos y metodos de uso
PT100472A (pt) Sequencias genomicas do virus da hepatite c e composicoes farmaceuticas que as contem, para diagnostico e terapeutica da hepatite c
BR0016145A (pt) Clones infecciosos
ES2064077T3 (es) Integracion estable de adn en genomas bacterianos.
ES2176342T3 (es) Secuencias del genotipo 7 del virus de la hepatitis c y su utilizacioncomo agentes profilacticos, terapeuticos y de diagnostico.
CA2303526A1 (en) Hepatitis c virus cell culture system
ATE507312T1 (de) Nachweis und typisierung das hepatitis c virus (hcv) mittels 5'utr und ns5 nukleinsäuresequenzen
DK0494955T3 (da) Cellefri syntese og isolering af hidtil ukendte gener og polypeptider
DK1017803T3 (da) Ekspression af endogene gener ved ikke-homolog rekombination af et vektorkonstrukt med cellulært DNA
ES2144399T3 (es) Clonado del adn de virus de anemia de los pollos.
AR014891A1 (es) Genes aislados de proteinas de membranas de mamiferos; reactivos relacionados
Mertens et al. Messenger RNA of infectious pancreatic necrosis virus is polycistronic
PT1298208E (pt) Ribozimas que abordam selectivamente uma sequencia tat do hiv
AR019250A1 (es) Formas atenuadas del virus de la diarrea viral bovina, molecula de acido nucleico, vector, uso, metodo para modificar el genoma viral de tipo salvaje, genoma modificado, vacuna, metodo para atenuar un virus bvd de tipo salvaje
BR0112020A (pt) Partìculas tipo vìrus de bvdv
AR017190A1 (es) Metodo para mejorar la resistencia o tolerancia a patogenos en una planta que comprende integrar en el genoma de dicha planta un gen que codificauna proteina de fusion que comprende una primer y segunda proteina o dominio de proteina con actividad antipatogenica, molecula de adn, su uso, proteinade
HRP20010230B1 (en) An in vitro activity assay for human hepatitis b virus (hbv)dna polymerase, and its use for screening for inhibitors of hbv dna polymerase
DE60040219D1 (de) Infektiöses cdna klon des gb-virus b und dessen verwendungen
ATE115964T1 (de) Non-a non-b sequenzen.
GT200200150A (es) Cadenas quimericas codificantes para proteinas inductoras de efectos contra virus
ATE346087T1 (de) Hepatitis e-virus aus dem schwein und dessen verwendungen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 856051

Country of ref document: ES